eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
4/2022
vol. 39
 
Share:
Share:
more
 
 
abstract:
Letter to the Editor

Sustained drug-related reaction with eosinophilia and systemic symptoms (DRESS) triggered by low molecular weight heparins in COVID-19: management and precision diagnosis

Elena Minenna
1, 2, 3
,
Nada Chaoul
3
,
Maria Pia Rossi
3
,
Lucia Giliberti
3
,
Marcello Albanesi
1, 3
,
Eustachio Nettis
3
,
Maria Pia Foschino Barbaro
2
,
Danilo Di Bona
3
,
Maria Filomena Caiaffa
1
,
Luigi Macchia
3

1.
Department of Medical and Surgical Sciences, Chair of Allergology and Clinical Immunology, University of Foggia, Foggia, Italy
2.
Department of Medical and Surgical Sciences, Chair of Respiratory Diseases, University of Foggia, Foggia, Italy
3.
Department of Emergency and Organ Transplantation, School and Chair of Allergology and Clinical Immunology, University of Bari – Aldo Moro, Bari, Italy
Adv Dermatol Allergol 2022; XXXIX (4): 816-818
Online publish date: 2021/10/01
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Low molecular weight heparins (LMWHs), particularly enoxaparin, are administered routinely to Coronavirus disease 2019 (COVID-19) patients, in order to treat or prevent the associated, possibly serious coagulation disorders [1].

Both immunoglobulin E (IgE)-mediated and non IgE-mediated systemic reactions to LMWHs are considered rare [2–4]. Particularly, a single case of the drug-related reaction with eosinophilia and systemic symptoms (DRESS) has been documented in the literature [4].

Here we report on an elderly COVID-19 patient who developed DRESS upon prophylactic treatment with enoxaparin. Etiological diagnosis was corroborated by the lymphocyte proliferation test (LPT) [5] upon recovery. The management strategy adopted is outlined and commented.
Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.